[{"address1": "500 North Beacon Street", "address2": "4th Floor", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "857 285 5300", "website": "https://www.kymeratx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 208, "companyOfficers": [{"maxAge": 1, "name": "Dr. Bruce L. Booth DPHIL, Ph.D.", "age": 50, "title": "Co-Founder & Independent Chairman", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 70000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nello  Mainolfi M.D., Ph.D.", "age": 45, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1979, "fiscalYear": 2024, "totalPay": 1226500, "exercisedValue": 1110312, "unexercisedValue": 37845672}, {"maxAge": 1, "name": "Mr. Bruce N. Jacobs CFA", "title": "Chief Financial Officer", "fiscalYear": 2024, "totalPay": 754540, "exercisedValue": 703665, "unexercisedValue": 9900757}, {"maxAge": 1, "name": "Dr. Jeremy G. Chadwick Ph.D.", "age": 61, "title": "Chief Operating Officer", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 719400, "exercisedValue": 0, "unexercisedValue": 838368}, {"maxAge": 1, "name": "Ms. Ellen V. Chiniara Esq., J.D.", "age": 65, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 696080, "exercisedValue": 0, "unexercisedValue": 1659227}, {"maxAge": 1, "name": "Dr. Jared A. Gollob M.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 768400, "exercisedValue": 3280617, "unexercisedValue": 6586792}, {"maxAge": 1, "name": "Ms. Justine E. Koenigsberg", "title": "Vice President of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen  Weisbach", "title": "Head of People & Culture", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Juliet  Williams B.A Ph.D.", "title": "Head of Research", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Noah  Goodman M.B.A.", "age": 37, "title": "Chief Business Officer", "yearBorn": 1987, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1748736000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 44.530003, "open": 45.04, "dayLow": 44.26, "dayHigh": 45.145, "regularMarketPreviousClose": 44.530003, "regularMarketOpen": 45.04, "regularMarketDayLow": 44.26, "regularMarketDayHigh": 45.145, "payoutRatio": 0.0, "beta": 2.074, "forwardPE": -14.40193, "volume": 240486, "regularMarketVolume": 240486, "averageVolume": 948088, "averageVolume10days": 1134620, "averageDailyVolume10Day": 1134620, "bid": 32.43, "ask": 57.06, "bidSize": 2, "askSize": 2, "marketCap": 3142341120, "fiftyTwoWeekLow": 19.445, "fiftyTwoWeekHigh": 53.27, "priceToSalesTrailing12Months": 53.364033, "fiftyDayAverage": 37.9978, "twoHundredDayAverage": 39.435974, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 2464997888, "profitMargins": 0.0, "floatShares": 41673919, "sharesOutstanding": 70157200, "sharesShort": 7582895, "sharesShortPriorMonth": 6995367, "sharesShortPreviousMonthDate": 1747267200, "dateShortInterest": 1749772800, "sharesPercentSharesOut": 0.1164, "heldPercentInsiders": 0.02499, "heldPercentInstitutions": 1.03646, "shortRatio": 7.15, "shortPercentOfFloat": 0.1471, "impliedSharesOutstanding": 70164096, "bookValue": 12.075, "priceToBook": 3.709317, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -240882000, "trailingEps": -3.11, "forwardEps": -3.11, "enterpriseToRevenue": 41.861, "enterpriseToEbitda": -9.074, "52WeekChange": 0.4014393, "SandP52WeekChange": 0.12677538, "quoteType": "EQUITY", "currentPrice": 44.79, "targetHighPrice": 79.0, "targetLowPrice": 53.0, "targetMeanPrice": 61.0, "targetMedianPrice": 60.0, "recommendationMean": 1.2, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 19, "totalCash": 463150016, "totalCashPerShare": 7.112, "ebitda": -271670016, "totalDebt": 86330000, "quickRatio": 8.191, "currentRatio": 8.492, "totalRevenue": 58885000, "debtToEquity": 10.98, "revenuePerShare": 0.761, "returnOnAssets": -0.19466999, "returnOnEquity": -0.32173002, "grossProfits": -212799008, "freeCashflow": -136320880, "operatingCashflow": -234060000, "revenueGrowth": 1.148, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -3.36769, "financialCurrency": "USD", "symbol": "KYMR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "longName": "Kymera Therapeutics, Inc.", "regularMarketChangePercent": 0.583872, "regularMarketPrice": 44.79, "postMarketTime": 1751576085, "regularMarketTime": 1751562001, "exchange": "NGM", "messageBoardId": "finmb_542085131", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "shortName": "Kymera Therapeutics, Inc.", "corporateActions": [], "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1598016600000, "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 948088, "fiftyTwoWeekLowChange": 25.345001, "fiftyTwoWeekLowChangePercent": 1.30342, "fiftyTwoWeekRange": "19.445 - 53.27", "fiftyTwoWeekHighChange": -8.48, "fiftyTwoWeekHighChangePercent": -0.15918903, "fiftyTwoWeekChangePercent": 40.143932, "earningsTimestamp": 1746788400, "earningsTimestampStart": 1754397000, "earningsTimestampEnd": 1754915400, "earningsCallTimestampStart": 1746799200, "earningsCallTimestampEnd": 1746799200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.11, "epsForward": -3.11, "epsCurrentYear": -3.51229, "priceEpsCurrentYear": -12.752364, "fiftyDayAverageChange": 6.792202, "fiftyDayAverageChangePercent": 0.17875251, "twoHundredDayAverageChange": 5.354027, "twoHundredDayAverageChangePercent": 0.13576505, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-08-21", "averageAnalystRating": "1.2 - Strong Buy", "postMarketChangePercent": 0.0, "postMarketPrice": 44.79, "postMarketChange": 0.0, "regularMarketChange": 0.259998, "regularMarketDayRange": "44.26 - 45.145", "displayName": "Kymera Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-07-05"}]